000 01228 a2200325 4500
005 20250517194315.0
264 0 _c20181031
008 201810s 0 0 eng d
022 _a1879-0852
024 7 _a10.1016/j.ejca.2017.12.004
_2doi
040 _aNLM
_beng
_cNLM
100 1 _aIbrahim, Sajida
245 0 0 _aPharmacokinetics partly explains the relationship between carcinoembryonic antigen level and survival of colorectal cancer patients treated with ramucirumab.
_h[electronic resource]
260 _bEuropean journal of cancer (Oxford, England : 1990)
_c03 2018
300 _a119-120 p.
_bdigital
500 _aPublication Type: Letter; Comment
650 0 4 _aAntibodies, Monoclonal
650 0 4 _aAntibodies, Monoclonal, Humanized
650 0 4 _aBiomarkers, Tumor
650 0 4 _aCarcinoembryonic Antigen
650 0 4 _aColorectal Neoplasms
650 0 4 _aHumans
650 0 4 _aRamucirumab
700 1 _aRaoul, William
700 1 _aLecomte, Thierry
700 1 _aPaintaud, Gilles
700 1 _aTernant, David
773 0 _tEuropean journal of cancer (Oxford, England : 1990)
_gvol. 92
_gp. 119-120
856 4 0 _uhttps://doi.org/10.1016/j.ejca.2017.12.004
_zAvailable from publisher's website
999 _c27975724
_d27975724